GenfitFRA:XUPB +10.81%68 Gross Margin % is 99.55% as of Dec. 2025, which is 1% above its 10-year median of 98.79. GuruFocus rates FRA:XUPB with a GF Score™ of 68/100 and a GF Value™ of €5.19. The stock has 10 warning signs investors should review. Among 734 Biotechnology companies, Genfit ranks better than 97.96% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Genfit's Gross Profit for the
six
months ended in Dec. 2025 was €31.80 Mil. Genfit's Revenue for the
six
months ended in Dec. 2025 was €31.95 Mil. Therefore, Genfit's Gross Margin % for the quarter that ended in Dec. 2025 was 99.55%.
The historical rank and industry rank for Genfit's Gross Margin % or its related term are showing as below:
FRA:XUPB'
s Gross Margin % Range Over the Past 10 Years
Min: -598.94 Med: 98.79 Max: 99.8
Current: 99.54
During the past 13 years, the highestGross Margin % of Genfit was 99.80%. The lowest was -598.94%. And the median was 98.79%.
FRA:XUPB's Gross Margin % is ranked better than 97.96% of 734
companies
in the Biotechnology industry
Industry Median: 60.795
vs FRA:XUPB: 99.54
Genfit had a gross margin of 99.55% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Genfit was 4.40% per year.
Genfit (FRA:XUPB) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Genfit had a gross margin of 99.55% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Genfit Gross Margin % Related Terms
Genfit Gross Margin % Historical Data
* Premium members only.
The historical data trend for Genfit's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:XUPB vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Genfit's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genfit Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genfit's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Genfit's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Genfit (FRA:XUPB) has a Gross Margin % of 99.55% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Genfit and its competitors. This is near median its historical median of 98.79. According to the industry distribution chart, Genfit ranks #15 out of 734 companies in the Biotechnology industry, placing it in the top 2%.
Is Genfit's Gross Margin % too high?
Genfit's current Gross Margin % of 99.55% is near median its 10-year median of 98.79. The Biotechnology industry median Gross Margin % is 60.80. Genfit's value of 99.55% is 63.7% above this industry median. Based on the distribution chart, Genfit ranks #15 out of 734 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genfit has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Genfit's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genfit ranks #15 out of 734 companies for Gross Margin %. This places Genfit in the top 2% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.80. Genfit's value of 99.55% is 63.7% above this benchmark. While the company's 10-year median is 98.79 vs. the industry median of 60.80, Genfit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genfit's current Gross Margin % of 99.55% is 63.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Genfit and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genfit's current Gross Margin % is 99.55%, which is near median its own 10-year median of 98.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genfit stock overvalued right now?
Genfit (FRA:XUPB) has a current Gross Margin % of 99.55%. The stock's GF Value™ is €5.19, compared to a current price of €6.15 — trading 18.5% above its estimated fair value. The current Gross Margin % is 99.55%, which is near median its 10-year median of 98.79 and 63.7% above the Biotechnology industry median of 60.80. Genfit's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Genfit (FRA:XUPB), the current Gross Margin % is 99.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genfit (FRA:XUPB) Overvalued in 2026?
Based on GuruFocus' analysis, Genfit stock appears to be overvalued.
The current stock price of €6.15 is trading 18.5% above its estimated GF Value™ of €5.19.
Key valuation signals for FRA:XUPB:
Gross Margin %: 99.55% (near median its 10-year median of 98.79)
GF Value™: €5.19 vs. price of €6.15 (18.5% above fair value)
Industry Position: 63.7% above the Biotechnology median (#15 of 734)
No single metric tells the full story. See the FRA:XUPB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements to fund the further development of its products. It has one segment, the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
68GF Score
Get the complete analysis for FRA:XUPB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XUPB has been successfully added to your 
